anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, mammology, gynecology, endocrinology. SUBSTANCE: medicinal preparation is suggested to be used in treating mastopathy based upon laminaria concentrate and other additional substances. The suggested preparation is obtained out of thallus, rhizoid and leaf stalks of brown algae of laminaria type, it contains not less than 0.1 mg iodine and 9 mg highest fatty acids per 1 tablet or capsule. "Mamoclam" is of pronounced curative action in mastopathy- suffering patients - diffuse fibrous-cystic disease of mammary glands: decreases mastalgia phenomena, syndrome of premenstrual tension and disalgomenorea, normalizes menstrual cycle, leads to regression of palpatory signs of fibroadenomatosis and cysts in mammary glands, improves mammographic picture. Thus, positive effect is observed in 94% patients. "Mamoclam" causes no side and toxic actions. EFFECT: higher efficiency of therapy. 2 cl, 2 tbl
A computer-implemented method for ordinal prediction is provided. The method includes encoding time series data with a temporal encoder to obtain latent space representations. The method includes optimizing the temporal encoder using semi-supervised learning to distinguish different classes in the labeled space using labeled data, and augment the latent space representations using unlabeled training data, to obtain semi-supervised representations. The method further includes discarding a linear layer after the temporal encoder and fixing the temporal encoder. The method also includes training k-1 binary classifiers on top of the semi-supervised representations to obtain k-1 binary predictions. The method additionally includes identifying and correcting inconsistent ones of the k-1 binary predictions by matching the inconsistent ones to consistent ones of the k-1 binary predictions. The method further includes aggregating the k-1 binary predictions to obtain an ordinal prediction.
All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
OBJECTIVE: This study aimed to test different AI-based face-swapping models applied to videos of epileptic seizures, with the goal of protecting patient privacy while retaining clinically useful seizure semiology. We hypothesized that specific models would show differences in semiologic fidelity compared to the original clinical videos.
METHODS: Three open-source models, SimSwap, MobileFaceSwap and GHOST were adopted for face-swapping. For every model, an AI generated male and female image were used to replace the original faces. One representative seizure per patient from three patients with epilepsy was chosen (3 seizure videos x 3 AI models x 2 M/F swap) and remade to 18 transformed video clips. To evaluate the performance of the three models, we used both objective (AI-based) and subjective (expert clinician) evaluation. The objective assessment included four metrics for facial appearance and four metrics for facial expression changes. Four experienced epileptologists reviewed the clips and scoring according to deidentification and preservation of semiology. Kruskal-Wallis H test was used for statistical analysis among the models.
RESULTS: In the reproduced videos, the swapped face cannot be recognized as the original face, with no significant difference in scores of deidentification either by objective or subjective assessment. Regarding semiology preservation, no significant differences between models were observed in the objective evaluations. The subjective evaluations revealed that the GHOST model outperformed the other two models (p=0.028).
CONCLUSION: This is the first study evaluating AI face swapping models in epileptic seizure video clips. Optimization of AI face-swapping models could enhance the accessibility of seizure videos for education and research while protecting patient privacy and maintaining semiology.
PURPOSE: An antimicrobial composition including hinokitiol having antimicrobial activity against Propionibacterium acne as an effective component is provided. It also has excellent antimicrobial activity against resident skin bacteria such as Staphylococcus epidermidis and Staphylococcus aureus and safety to the human body. CONSTITUTION: An antimicrobial composition against resident skin bacteria contains 0.0001 to 20% by weight of hinokitiol. The hinokitiol is extracted from one or more plants selected from the group consisting of Taiwanese Chamaecyparis obtusa, Thujopsis dolabrata Sieb. et Zucc. and Juniperus chinensis L.
Obesity is a major risk factor for liver and cardiovascular diseases. However, obesity-driven mechanisms that contribute to the pathogenesis of multiple organ diseases are still obscure and treatment is inadequate. We hypothesized that increased , glucose-6-phosphate dehydrogenase (G6PD), the key rate-limiting enzyme in the pentose shunt, is critical in evoking metabolic reprogramming in multiple organs and is a significant contributor to the pathogenesis of liver and cardiovascular diseases. G6PD is induced by a carbohydrate-rich diet and insulin. Long-term (8 months) high-fat diet (HFD) feeding increased body weight and elicited metabolic reprogramming in visceral fat, liver, and aorta, of the wild-type rats. In addition, HFD increased inflammatory chemokines in visceral fat. Interestingly, CRISPR-edited loss-of-function Mediterranean G6PD variant (G6PDS188F) rats, which mimic human polymorphism, moderated HFD-induced weight gain and metabolic reprogramming in visceral fat, liver, and aorta. The G6PDS188F variant prevented HFD-induced CCL7 and adipocyte hypertrophy. Furthermore, the G6PDS188F variant increased Magel2 - a gene encoding circadian clock-related protein that suppresses obesity associated with Prader-Willi syndrome - and reduced HFD-induced non-alcoholic fatty liver. Additionally, the G6PDS188F variant reduced aging-induced aortic stiffening. Our findings suggest G6PD is a regulator of HFD-induced obesity, adipocyte hypertrophy, and fatty liver.
The present invention relates to a mixture of soluble hydrophobic peptides of an enzymatic hydrolysate of milk having skin hydrating properties and percutaneous absorption levels of 4 to 5%. The mixture also exhibits wound healing properties but does not have the allergenicity of the milk protein. One fraction of the mixture is capable of increasing in vitro the growth rate of cell-cultured keratinocytes by at least 50%. The soluble hydrophobic peptides of the fraction have a molecular weight of about 2000 daltons ranging from 1400 to 2600 daltons The soluble peptides are constituted of 66% hydrophobic amino acids and 17% aromatic amino acids, and have aromatic amino acids and other hydrophobic amino acids located at the C- and N-terminal ending in proportion over 85%. Another fraction is capable of increasing the growth rate of cell-cultured fibroblasts by 37% and the production of collagen by 73%.. The hydrolysate and peptides of the present invention can be formulated in cosmetic composition, in skin cell culture medium and in wound healing composition.
BACKGROUND: Metaplastic breast carcinomas are a rare variant group of breast carcinomas. They are usually high-grade and triple-negative tumors. They often present with large primary tumor sizes. However, the involvement of axillary lymph nodes is infrequent at the time of diagnosis. Metaplastic breast carcinomas are associated with a worse prognosis and a poorer response to chemotherapy in comparison with other non-metaplastic triple-negative breast cancers. Up until this point, there are no specific treatment recommendations for metaplastic breast carcinomas beyond those intended for invasive breast cancer in general.
CASE PRESENTATION: A 40-year-old woman complained of a palpable mass in her left axilla. On ultrasonography, the mass was solid, spindle-shaped, hypoechoic with regular borders, and exhibited decreased vascularity. At first, the mass appeared to be of a muscular origin. There was not any clinical nor ultrasonic evidence of a primary breast tumor. On magnetic resonance imaging, the axillary mass was a well-defined with regular borders, measuring 24 × 35 mm. Needle biopsy showed a spindle cell tumor with mild to moderate atypia. The subsequent surgical resection revealed a spindle cell neoplasm within a lymph node, favoring a metastatic origin of the tumor. The tumor cells lacked expression of estrogen, progesterone, and HER2 receptors. PET-CT scan indicated pathological uptake in the left breast. Accordingly, the patient was diagnosed with metaplastic breast cancer that had metastasized to the axillary lymph node. She commenced a combined chemotherapy regimen of doxorubicin and cyclophosphamide. After six treatment cycles, she underwent left modified radical mastectomy with axillary lymph node dissection. Pathological examination of the specimens revealed a total burn-out tumor in the breast due to excellent treatment response. There were no residual tumor cells. All dissected lymph nodes were free of tumor. At the one-year follow-up, the patient showed no signs of tumor recurrence.
CONCLUSION: This report sheds light on a distinctive presentation of metaplastic breast carcinoma, emphasizing the need for vigilance in diagnosing this rare and aggressive breast cancer variant. In addition, the patient's remarkable response to chemotherapy highlights potential treatment avenues for metaplastic breast cancer.
The present invention relates to a pharmaceutical composition for treating or preventing thrombosis diseases, and to a thrombogenesis inhibitor. The pharmaceutical composition and the thrombogenesis inhibitor according to the present invention use a material extracted from a natural material, and thus inhibit thrombogenesis by inhibiting the coagulation of platelets without a side effect. In particular, even when the pharmaceutical composition or the thrombogenesis inhibitor is used for a long time or a large quantity thereof is used, proteins other than thrombus are not decomposed. Thus, there is not a side effect (blooding delay problem) shown when a blood barrier or other proteins in blood are decomposed, and a thrombogenesis inhibiting effect can be sufficiently achieved even through oral administration. Such an effect is ensured by remarkably remedying a side effect of a conventional thrombogenesis inhibitor. Moreover, materials derived from a natural material and having a thrombogenesis inhibiting effect are diversified.
BACKGROUND: The prevalence of long-term opioid use after orthopaedic surgery varies from 1.4% to 24% and has mostly been studied with prescription data, making it difficult to estimate the size and impact of the problem. This study aims to assess the prevalence and predictors of long-term postoperative opioid use in a high volume and tertiary orthopaedic centre by using online patient reported measures.
METHODS: This Dutch prospective cohort study was conducted among adult patients who underwent any type of orthopaedic surgery from June to August 2021. Six months after surgery patients were invited to complete an online survey on current opioid use and patients' willingness to taper opioids. The demographics, clinical factors and preoperative opioid use were extracted from the patient file.
RESULTS: In total, 607 patients (mean age 61.2 years, 63.4% female) completed the survey. Seventy-six patients (12.5%) used opioids 6 months after surgery of which 20 (3.3%) did not use opioids before surgery. The median (Q1-Q3) postoperative daily dose after 6 months was 29.9 mg (10.0-76.1) morphine equivalents. Most of them (88.2%) wanted to taper opioids. Affected body region (OR's: 6.84-12.75) and pre-operative opioid use (OR = 35.33) were significant predictors of long-term opioid use.
CONCLUSION: The prevalence of long-term postoperative opioid use was 12.5%; one in thirty patients became a new long-term opioid user. Pre-operative opioid use and affected body region were predictive for long-term opioid use. These findings, together with the observation that long-term opioid users want to taper opioids, emphasize the relevance of prevention, recognition and tapering support in the perioperative setting.
LEVEL OF EVIDENCE: Level II.
SIGNIFICANCE: Short-term opioid use can unintentionally progress to long-term opioid use. The prevalence of long-term opioid use after orthopaedic surgery varies widely and is mostly prescription-based, making it difficult to estimate the magnitude of the problem. This study assessed long-term postoperative opioid use in a full breadth orthopaedic population using patient reported measures, making conclusions much more robust. The prevalence of long-term postoperative opioid use in this study was 12.5%.
BACKGROUND: The health crisis due to Covid-19 led to the search for therapeutics that could improve the evolution of the disease. Remdesivir, an antiviral that interferes with viral replication, was one of the first to be used for the treatment of this pathology.
OBJECTIVE: To determine clinical course and mortality of patients with severe SARS-CoV-2 pneumonia treated with remdesivir, in comparison of those who didn't receive the medication.
PATIENTS AND METHODS: Retrospective cohort study, with medical records review of COVID-19 patients, between August 2020 and August 2021. The subjects were divided into two groups, those who received remdesivir before or after admission to intensive care and those who didn't. The primary outcome variable was mortality in intensive care.
RESULTS: Of 214 subjects included, 109 (50,9%) received remdesivir. The median of days for the drug administration was 8 (2-20), IQR: 3. The bivariate analysis prove that the use of remdesivir was related with lower risk of develop Acute Respiratory Distress Syndrome (ARDS) (p = 0,019; OR: 0,521) and lower requirement of mechanical ventilation (p = 0,006; OR:0,450). Additionally, patients treated with remdesivir develop less kidney injury (p = 0,009; OR: 0,441). There was a total of 82 deaths, 29 (26,6%) in the remdesivir group and 53 (50,5%) in the control group [p < 0,001; OR: 0,356 (0,201-0,630)]. All the risk factors associated with mortality in the bivariate analysis were entered into the multivariate analysis by logistic regression, the use of remdesivir remained associated as an independent protective factor to mortality (p = 0.034; OR: 0.429).
CONCLUSION: Critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir had a lower risk of death and need for mechanical ventilation and develop less ARDS as compared to the control group. No differences were found in the presentation of adverse effects.
The present invention relates to the application of the realgar microorganism leaching solution in anti tumor medicine preparation. The realgar microorganism leaching solution is prepared according to the exposed microorganism treating method in patent 2006102000675. The realgar leaching solution in the present invention has a profound inhabiting effect in a plurality of cancer disease comprising cancer of the liver, gastric cancer, leukemia and lung cancer. In addition, the application quantity is in level of microgram. Furthermore, because the realgar microorganism leaching solution is a dissoluble medicine, therefore the medicine can be applied respectively or applied in combination with other drugs, or with pharmaceutical acceptable excipient. The medicine is easy to be produced as various kinds of preparations, which comprises guttate pills, aerosol, vinum, syrups, oral application liquid, injection and injectable powder.
Epilepsy, a common neurological disorder, is characterized by paroxysmal, short-term, repetitive, and stereotypical features, significantly impacting patients' quality of life. Currently, the pathogenesis of epilepsy remains incompletely understood. Changes in neuronal excitability, imbalances in glutamate and gamma-aminobutyric acid (GABA) levels, alterations in the activity of GABA receptors, and dysfunction of GABA receptors are considered closely related to its occurrence. Thyroid hormones, vital for human growth and development, also play a crucial role in the nervous system. They mediate oxidative stress, influence reactive oxygen species production, affect mitochondrial function and neuronal excitability, and modulate glutamate and GABA levels. Also, they combine with thyroid hormone receptors and exert genomic effects by regulating the expression of numerous genes. However, once there are defects in thyroid hormone signaling, these defects may lead to severe neurodevelopmental disorders that are associated with an increased frequency of seizures. The impact of antiseizure medications (ASMs) on serum thyroid hormone levels, particularly traditional ASMs, has been extensively studied. It is reported that conventional ASMs such as phenobarbital, phenytoin sodium, carbamazepine, and valproate sodium were more likely to induce subclinical hypothyroidism (elevated TSH with normal FT4) or isolated hypothyroidism (decreased FT4 with normal TSH). However, the new ASMs, such as levetiracetam, have no effect on thyroid hormone levels. Together, seizures not only affect thyroid hormone levels, but abnormal thyroid hormone levels can also influence seizures. However, the precise mechanism underlying the interaction between serum thyroid hormone levels and seizures remains unclear. This review aims to explore the relationship between thyroid hormone levels and seizures, along with the underlying mechanisms.
The present invention addresses the problem of providing a mayenite compound that can induce electron donation reactions, H -  donation reactions, deoxygenation reactions, and dehydration reactions. The present invention also addresses the problem of providing a multifunctional agent that includes the mayenite compound, that does not dissolve in a solvent, and that can induce electron donation reactions, H -  donation reactions, deoxygenation reactions, and dehydration reactions. The present invention also addresses the problem of providing a production method for a mayenite-compound-containing product. A mayenite compound that is characterized by encapsulating electrons and H - . A multifunctional agent that is characterized by containing the mayenite compound I and/or a mixture II of a mayenite compound that encapsulates electrons and a mayenite compound that encapsulates H - , by being reducible, and by having radical elimination activity, deoxygenation functionality, and dehydration functionality. A production method for a mayenite-compound-containing product that contains the mayenite compound.
A method of treating a cell proliferative disorder including types of cancer, causes inhibition of blood supply to the cancerous region, eg., a tumor, by administering an admixture of a predetermined quantity of a polyunsaturated fatty acid in the form of a solution of at least one polyunsaturated fatty acid together with optionally a predetermined anticancer drug, a cytokine and an oily lymphographic agent. In a preferred form, the admixture is injected intra-arterially through a catheter into an artery which provides the major blood supply to the tumor, the artery being proximate to the tumor. The solution of the polyunsaturated fatty acid may comprise an essential fatty acid(s) metabolite in salt form, eg., a lithium salt for non-glioma type of tumor, and a sodium/potassium salt for treating glioma. The polyunsaturated fatty acid content in the admixture may be in the range of 0.5 mg to 50 gm. The cytokine (lymphokine) may be tumor necrosis factor and/or interferon. The admixture may be administered orally or parenterally or by methods which are selective combinations, eg., intra-arterial, oral and parenteral. Examples given of cancers treated include hepatoma, giant cell tumor of the bone and glioma. The invention by cutting off blood supply to the tumor region causes massive necrosis of the cancerous cells, and prevents angiogenic activity in the tumor region.
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
The invention relates to a spray for treating dysmenorrheal. The spray comprises the following raw materials in parts by weight: 8 parts of cottonseed, 7-9 parts of Syzygium aromaticum, 6-8 parts of radix angelicae pubescentis, 6-8 parts of liquidambar formosana hance, 7-8 parts of leonurus and 8-9 parts of flowers carthami. The spray provided by the invention has the beneficial effects that the spray is delivered directionally and transdermally absorbed and convenient to use, and treats inner diseases outside. The spray avoids irritation to stomach and toxic and side effects to liver and does not affect normal diet habit of patients. The effective components in the spray cannot be damaged by digestive juice, and the effect is not reduced due to the first pass effect of liver, so that the spray can be quickly and better absorbed by patients. The spray can activate blood to promote menstruation, improve the state of uterus and relive pain after being sprayed in the triangular area of the uterus for 3-10 minutes. Dysmenorrheal spondylosis can be cured in 3-6 months. The spray is safe, efficient, extract in medical effect and high in treatment rate, and a novel dosing manner is created, and the spray is of initiativeness.
Depression, projected to be the predominant contributor to the global disease burden, is a complex condition with diverse symptoms including mood disturbances and cognitive impairments. Traditional treatments such as medication and psychotherapy often fall short, prompting the pursuit of alternative interventions. Recent research has highlighted the significant role of gut microbiota in mental health, influencing emotional and neural regulation. Fecal microbiota transplantation (FMT), the infusion of fecal matter from a healthy donor into the gut of a patient, emerges as a promising strategy to ameliorate depressive symptoms by restoring gut microbial balance. The microbial-gut-brain (MGB) axis represents a critical pathway through which to potentially rectify dysbiosis and modulate neuropsychiatric outcomes. Preclinical studies reveal that FMT can enhance neurochemicals and reduce inflammatory markers, thereby alleviating depressive behaviors. Moreover, FMT has shown promise in clinical settings, improving gastrointestinal symptoms and overall quality of life in patients with depression. The review highlights the role of the gut-brain axis in depression and the need for further research to validate the long-term safety and efficacy of FMT, identify specific therapeutic microbial strains, and develop targeted microbial modulation strategies. Advancing our understanding of FMT could revolutionize depression treatment, shifting the paradigm toward microbiome-targeting therapies.
The present invention relates to a nose ointment for preventing common cold, it is prepd. from folium hibisci, radix sanguisorbae, menthol, borneol, edible vinegar according to existent prodn. technology. The product is a yellowish brown ointment. Its advantages include: simple prepn. method, low cost for application, good effect in preventing and curing influenza and common cold.
Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.